1/13

F1G.	SUBCLASS		
0.G. FI	CLASS		
APPROVED	) (C1	<b>DRAFTSHAN</b>	

D9509418 .. 071100




Figure 1



APPROVED O.G. F1G.

DY CLASS SUBCLASS
DRAFTSMAN

WO 99/15648






Figure 2





0.05 µM

OLIGO TREATMENT (DAYS)

 $0.05~\mu M$ 

0.10 µM

Figure 3

0.10 µM

0.G. F1G.	CLASS SUBCLASS	
APPROVED	ò	DRAFISMAN






Figure 4


5/13





Control (Tomudex-treated, no oligo) 0 Oligo 83 (0.10 µM) Oligo 81 (0.10 µM) Δ

Figure 5



D9509418.071100





Figure 6

APPROYED O.G. FIG.
BY CLASS SUBCLASS

## (first 80 bases in TS mRNA not shown)



## Figure 7




FIGURE 8




FIGURE 9

WO 99/15648




FIGURE 10

WO 99/15648






FIGURE 11



Time after transfection (days)

FIGURE 12



SUBSTITUTE SHEET (RULE 26)